If you have spent years trying antidepressant after antidepressant without finding real relief, you are not alone. Many people reach a point where they have worked through multiple medications, adjusted dosages, switched prescribers, and still find themselves stuck in the same heavy fog. When a doctor finally mentions ketamine-based treatments, it can feel like a door opening. But then comes the next wave of confusion: SPRAVATO or IV ketamine? Nasal spray or infusion? FDA-approved or off-label? What does any of this actually mean for you?
This is a question we hear regularly at our clinic. Patients come in having read fragments of information online, sometimes hopeful, sometimes skeptical, and almost always uncertain about which path makes more sense for their specific situation. The two treatments are genuinely related; they share a chemical foundation and a mechanism of action, but they are not the same thing. They differ in how they are delivered, how they feel during treatment, how they are regulated, and how insurance treats them.
This article is meant to give you a clear, honest picture of both options before you sit down with a clinician. We are not here to steer you toward one over the other. The right choice depends on your history, your goals, and a thorough evaluation. What we can do is make sure you walk into that conversation informed, so you can ask better questions and feel more confident in whatever direction your care team recommends.
To understand the difference between SPRAVATO and IV ketamine, it helps to start with a bit of basic chemistry explained in plain terms.
Ketamine has been used in medicine since the 1960s, originally as an anesthetic for surgery. It is a dissociative compound, meaning it can alter perception and create a sense of detachment from one’s surroundings at higher doses. Over the past few decades, researchers and clinicians began noticing that patients receiving ketamine for other reasons sometimes reported rapid improvements in mood – a finding that eventually led to serious investigation into its antidepressant potential.
Here is where the chemistry matters. Ketamine is what pharmacologists call a racemic mixture. Think of it like a pair of gloves: the molecule exists in two mirror-image forms that are structurally identical but cannot be superimposed on each other. These are called enantiomers. In the case of ketamine, the two forms are R-ketamine and S-ketamine.
SPRAVATO is the brand name for esketamine, which is the S-enantiomer isolated and purified on its own. So, esketamine is derived from ketamine but is not the same compound. It is one-half of the original molecule, separated and delivered through a different route. For a deeper look at how these two compounds compare clinically, the esketamine vs. ketamine therapy for depression overview covers the key distinctions in detail.
IV ketamine infusions use the full racemic mixture – both the R and S forms together – delivered directly into the bloodstream through an intravenous line. SPRAVATO, by contrast, is absorbed through the nasal mucosa, the tissue lining the inside of the nose. This difference in delivery pathway is not a small detail. It affects how quickly the drug reaches the brain, how much of it actually gets absorbed, and what the clinical experience feels like during treatment.
There is also an important regulatory distinction. SPRAVATO received FDA approval in March 2019 for treatment-resistant depression in adults, and then again in August 2020 for major depressive disorder with acute suicidal ideation or behavior. Those are specific, defined indications backed by clinical trial data submitted to the FDA.
IV ketamine, on the other hand, is FDA-approved as an anesthetic – not as an antidepressant. When clinicians use it to treat depression, that is considered off-label use. Off-label prescribing is legal and common in medicine, and there is a substantial body of clinical research supporting ketamine’s antidepressant effects. Understanding the different types of ketamine and why one size doesn’t fit all can help clarify why clinicians choose one form over another for specific patients. But the absence of an FDA-approved depression indication has real consequences for how insurance treats it, which we will cover in a later section.
One of the most common questions patients ask is simply: What will actually happen to me during the appointment? Both treatments take place in a clinical setting under medical supervision, but the experience of each is meaningfully different.
An IV ketamine session typically lasts around 40 minutes, though the full appointment, including preparation and monitoring, will take longer. A nurse or clinician places an IV line, and the ketamine is delivered at a carefully controlled rate directly into your bloodstream.
Because the drug enters circulation immediately, the onset of effects is rapid. Many patients experience some degree of dissociation, a feeling of mental distance from their surroundings, altered perception of time, visual changes, or a dreamlike quality. The intensity of this experience varies from person to person and can be influenced by the dose used. Some patients find it peaceful or even meaningful. Others find it disorienting. Your care team will be present throughout and can adjust if needed.
After the infusion ends, the acute effects wear off relatively quickly, but you will still need someone to drive you home. You should not operate a vehicle or make important decisions for the rest of the day. Most clinics recommend resting afterward and avoiding alcohol or stimulants. Reviewing what to expect from ketamine therapy sessions before your first appointment can help you feel more prepared for the process.
The SPRAVATO experience looks different from the outside but shares some of the same precautions. Because of its FDA approval status, SPRAVATO is dispensed through a Risk Evaluation and Mitigation Strategy program, known as a REMS program. This is a formal FDA safety framework that requires the medication to be administered and monitored in a certified healthcare setting. You cannot take SPRAVATO home.
During a session, you self-administer the nasal spray under clinical supervision. Two doses are given approximately five minutes apart. After administration, you remain in the office for a mandatory two-hour monitoring period. During this time, staff monitor your blood pressure, observe for any dissociative symptoms, and ensure you are stable before you leave.
As with IV ketamine, you cannot drive yourself home after a SPRAVATO session. The monitoring period and transportation requirement are non-negotiable parts of the protocol, not optional add-ons.
The dissociative effects with SPRAVATO tend to be present but often less intense than what many patients describe with IV infusions, partly because nasal absorption is less direct than intravenous delivery. That said, individual responses vary, and some patients do experience perceptual effects. Your care team will walk you through what to expect during esketamine treatment before your first session.
Both SPRAVATO and IV ketamine are recognized in clinical literature for something that sets them apart from virtually every traditional antidepressant: the potential for rapid relief. Where SSRIs and SNRIs typically require weeks of consistent use before any mood improvement becomes apparent, some patients receiving ketamine-based treatments report noticeable shifts within hours to days of their first session. That speed of onset is clinically significant, particularly for patients in acute distress. Research into why ketamine works faster than traditional antidepressants points to its unique mechanism of action on glutamate receptors rather than serotonin pathways.
That said, rapid onset does not mean permanent relief from a single treatment. Both options require ongoing protocols to maintain their effects.
IV ketamine is typically administered as an initial series of infusions, often several sessions over a few weeks, followed by periodic booster infusions to sustain the antidepressant effect. The spacing of those boosters varies by clinic and by patient response. Some people find that their relief holds well between sessions; others need more frequent maintenance. There is no single universal protocol, which is one of the reasons IV ketamine can feel more flexible but also less standardized.
SPRAVATO follows a more structured, FDA-defined maintenance schedule. The typical protocol begins with twice-weekly sessions for four weeks, then transitions to weekly sessions, and eventually to every one to two weeks as a long-term maintenance phase. SPRAVATO is also intended to be used alongside an oral antidepressant, not as a standalone treatment. This combination approach is part of how it was studied and approved.
SPRAVATO’s FDA approval is grounded in clinical trial data, including the TRANSFORM trial program, which evaluated esketamine in patients with treatment-resistant depression. The FDA reviewed that data and determined the benefit-risk profile supported approval. That is a meaningful distinction in terms of regulatory confidence.
IV ketamine has a robust and growing body of clinical research supporting its antidepressant effects, and many clinicians consider it highly effective. Understanding what ketamine maintenance therapy involves and who needs it can help patients set realistic expectations about the long-term commitment either treatment requires. We always recommend that patients discuss both the evidence base and any remaining uncertainties with their prescribing clinician rather than concluding online summaries alone.
For many patients, the financial side of treatment is not a minor consideration; it is a deciding factor. Here is how the two options differ in practical terms.
Because SPRAVATO is FDA-approved for treatment-resistant depression, it has a defined insurance reimbursement pathway. Many insurance plans, including Medicare and some commercial plans, may cover SPRAVATO when specific criteria are met. Typically, this requires documented evidence that a patient has tried and not responded to at least two different antidepressant medications. The prior authorization process can take time and requires thorough documentation, but for patients who qualify, insurance coverage can make SPRAVATO significantly more accessible financially.
The in-office administration and monitoring requirements are also billable under certain codes, which is part of how the REMS program is structured to work within the healthcare billing system.
IV ketamine infusions are generally not covered by insurance for depression treatment because the indication is off-label. Most patients pay out of pocket, and costs vary depending on the clinic, geographic location, and number of sessions included in a package. A detailed breakdown of IV ketamine treatment and insurance coverage can help you understand what to ask your provider before committing to a treatment plan. It is worth asking any clinic you consider about their full pricing structure, what is included in a treatment series, and what follow-up looks like after the initial protocol.
Some patients find that IV ketamine is worth the out-of-pocket investment given their history and the severity of their symptoms. Others find SPRAVATO’s potential for insurance coverage to be a decisive advantage. Neither position is wrong; it depends on your financial situation and what your insurance will actually cover after a thorough benefits review.
Regardless of which treatment you pursue, neither is a shortcut around proper psychiatric care. Both require a formal psychiatric evaluation and a documented history of prior treatment attempts. These are advanced options for people who have already worked through conventional routes, not first-line treatments for someone newly diagnosed with depression. A thorough evaluation is the right starting point, and any reputable clinic will require it before recommending either option.
The more useful question is which treatment is a better fit for this specific person, at this point in their treatment history
SPRAVATO tends to be a particularly good option for patients who want an FDA-approved treatment pathway, which some find reassuring from a safety and regulatory standpoint. It may also be preferable for patients whose insurance is likely to cover it, since that can dramatically reduce the financial burden. Patients who are comfortable with a structured, recurring schedule coming in twice weekly at first and then gradually spacing out visits often do well with the SPRAVATO nasal spray protocol. It also suits patients who are willing to continue an oral antidepressant alongside the treatment, as that combination is built into how SPRAVATO is prescribed.
IV ketamine may be the better direction for patients who have not responded to SPRAVATO or who have a clinical profile that their prescriber believes would benefit from a different dosing approach or delivery method. Some clinicians also find IV ketamine useful when more precise dose titration is needed, since intravenous delivery allows for real-time adjustments in a way that a fixed-dose nasal spray does not. Patients who have tried multiple treatment modalities and are looking for a different angle may find that learning about the RMOKI ketamine treatment protocol opens a path that other options have not.
It is worth saying clearly: choosing one treatment does not close the door on the other. Some patients begin with SPRAVATO and later transition to IV ketamine, or vice versa. Treatment-resistant depression is a complex condition, and the path forward is rarely a straight line. What matters most is that the decision is made thoughtfully, in partnership with a clinician who knows your full history, not based on which option sounds better in an online article.
We always encourage patients to resist the urge to self-select a treatment before their evaluation. The clinical picture often looks different once a thorough assessment is completed, and a recommendation made with full context is far more reliable than one made based on general information alone.
If you have read this far, you are probably someone who has been through a lot already, multiple medications, possibly therapy, possibly other interventions, and you are trying to figure out whether ketamine-based treatment might finally offer something different.
At our clinic, a first appointment is not a sales conversation. It is a psychiatric evaluation. We review your full treatment history, discuss what has and has not worked, talk through your current symptoms and goals, and then have an honest conversation about which options make sense for your specific situation. Sometimes those points clearly point toward SPRAVATO. Sometimes it points toward IV ketamine. Sometimes the evaluation reveals that a different approach altogether, such as deep TMS for treatment-resistant depression or neurofeedback, might be a better starting point. We follow the clinical evidence, not a preference for one service over another.
The question of “SPRAVATO vs. ketamine” is genuinely nuanced, and the right answer is personal. No article, however thorough, can substitute for a conversation with a clinician who has reviewed your history and understands your goals.
If you are ready to take that next step, we are here. You can reach out to ask questions, request information, or schedule an evaluation. There is no pressure, no predetermined recommendation waiting for you, just a team that takes treatment-resistant depression seriously and wants to help you find a real path forward.
Neither treatment is universally superior. Both have helped patients who had run out of other options. The right choice depends on your history, your insurance situation, your comfort with each protocol, and a thorough clinical evaluation.
At Delray Brain Science, we offer both SPRAVATO and IV ketamine, along with TMS therapy, neurofeedback, and comprehensive psychiatric care. Our goal is to match you with the approach that fits your specific needs, not to push you toward any single service. If you have been struggling with treatment-resistant depression and want to explore your options, we would welcome the chance to talk.
Learn more about our services and take the first step toward a treatment plan built around your unique situation.
